TERT promoter mutation designates biologically aggressive primary glioblastoma

Neuro-Oncology

Volumn 17, Issue 1, 2015, Pages 5-6

  Huse, Jason T ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC AGENT; TELOMERASE REVERSE TRANSCRIPTASE; TEMOZOLOMIDE; TELOMERASE;

BRAIN SURGERY; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER PROGNOSIS; EDITORIAL; GENE FREQUENCY; GENE MUTATION; GENOTYPE; GLIOBLASTOMA; GLIOMA; HUMAN; MOLECULAR GENETICS; PROMOTER REGION; SURVIVAL RATE; TELOMERE HOMEOSTASIS; TUMOR INVASION; WILD TYPE; FEMALE; GENETICS; MALE; MORTALITY; MUTATION;

FEMALE; GLIOBLASTOMA; HUMANS; MALE; MUTATION; TELOMERASE;

EID: 84922513744     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nou318     Document Type: Editorial

References (10)

1. Huse JT, Aldape KD. The molecular landscape of diffuse glioma and prospects for biomarker development. Expert Opin Med Diagn. 2013;7(6):573-587.
2. Horn S, Figl A, Rachakonda PS, et al. TERT promoter mutations in familial and sporadic melanoma. Science (New York, N.Y. 2013; 339(6122):959-961.
3. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA. Highly recurrent TERT promoter mutations in human melanoma. Science (New York, N.Y. 2013;339(6122):957-959.
4. Killela PJ, Reitman ZJ, Jiao Y, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A. 2013; 110(15):6021-6026.
5. Simon M, Hosen I, Gousias K, et al. TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas. Neuro Oncol. 2015;14(1):45-52.
6. Jiao Y, Killela PJ, Reitman ZJ, et al. Frequent ATRX, CIC, and FUBP1 mutations refine the classification of malignant gliomas. Oncotarget. 2012;3(7):709-722.
7. Kannan K, Inagaki A, Silber J, et al. Whole exome sequencing identified ATRX mutation as a key molecular determinant in lower-grade glioma. Oncotarget. 2012;3:1194-1203.
8. Rachakonda PS, Hosen I, de Verdier PJ, et al. TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism. Proc Natl Acad Sci U S A. 2013;110(43):17426-17431.
9. Brennan CW, Verhaak RG, McKenna A, et al. The somatic genomic landscape of glioblastoma. Cell. 2013;155(2):462-477.
10. Wiestler B, Capper D, Holland-Letz T, et al. ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta neuropathologica. 2013;126(3):443-451.